Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of balovaptan in adults with autism spectrum disorder
2017-004378-32Phase 3Completed
- Sponsor
- Roche
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Balovaptan 10 mg with Placebo (2 arms). Primary endpoint: Change from baseline at Week 24 on the Vineland-II two-domain composite (2DC) score. Started May 2018; status: completed.
02
Drugs
balovaptan
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2017-004378-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004378-32.